Polycystic ovary syndrome (PCOS)

Polycystic ovary syndrome, commonly referred to as PCOS, is a complex endocrine and metabolic condition characterized by a variable association of ovulatory dysfunction, hyperandrogenism and ovarian morphological and functional abnormalities, in the absence of other disorders capable of explaining the same clinical presentation. It is therefore not a disease confined to the ovary, but a systemic disorder in which the hypothalamic pituitary ovarian axis, insulin metabolism, adipose tissue, follicular function and cardiometabolic risk interact dynamically. The historical name emphasizes the ovarian appearance, but clinically the syndrome includes reproductive, metabolic, dermatological and psychological manifestations that may occur in different combinations throughout the reproductive lifespan.

The clinical importance of PCOS reflects both its high prevalence and its potential presentation with amenorrhea or oligomenorrhea, anovulatory infertility, acne, hirsutism, weight gain, insulin resistance, impaired glucose tolerance and an increased risk of endometrial hyperplasia when anovulation persists over time. The syndrome may already be evident during adolescence or may emerge later, when irregular menstrual cycles, reproductive difficulties or metabolic abnormalities raise clinical suspicion. PCOS therefore requires an assessment that extends beyond the ovarian ultrasound appearance and integrates pathophysiology, long term risk and the patient’s specific goals.

PCOS is one of the most common endocrine disorders of the reproductive years. Its prevalence varies according to the diagnostic criteria used, the population studied and the ethnic and geographic setting, but contemporary analyses based on the updated Rotterdam criteria place it within a high prevalence range, making it a public health issue as well as a specialist gynecological or endocrinological diagnosis. Epidemiological heterogeneity is not merely numerical. It also reflects the syndromic nature of the condition, in which phenotypes dominated by hyperandrogenism, anovulation or metabolic abnormalities may differ in clinical visibility and therefore in the likelihood of diagnosis.

The age distribution shows that the syndrome is most commonly recognized during late adolescence and early adulthood, although many patients receive a diagnosis only after years of symptoms. This delay results from a tendency to attribute menstrual irregularities, acne, difficulty losing weight or excessive hair growth to unrelated “functional” problems. In fact, the coexistence of these manifestations should prompt early consideration of the syndrome, particularly when menstrual dysfunction persists beyond the physiological period of pubertal adjustment or when signs of androgenization are progressive.

The risk of PCOS has both a familial and an environmental component. First degree relatives with ovulatory irregularities, type 2 diabetes, visceral obesity, hyperandrogenic disorders or anovulatory infertility are frequently identified, suggesting a shared biological susceptibility. The genetic component does not follow a simple Mendelian pattern, but appears polygenic and intertwined with factors that regulate insulin secretion, peripheral insulin sensitivity, ovarian steroidogenesis and neuroendocrine regulation of gonadotropins.

The most clinically relevant risk factors include overweight, abdominal obesity and a personal history of rapid weight gain, because excess adipose tissue worsens insulin resistance, amplifies compensatory hyperinsulinemia and promotes an endocrine environment that accentuates ovulatory dysfunction and hyperandrogenism. However, PCOS is not synonymous with obesity. A substantial proportion of women with the syndrome have normal body weight, but still retain a profile of metabolic and reproductive vulnerability requiring equally careful diagnostic attention.

Ethnic background and geographic setting also influence prevalence and phenotype. Some populations have a higher prevalence or a greater tendency to develop insulin resistance, central adiposity, acne or hirsutism at an early stage, while in other groups clinical hyperandrogenism may be less apparent despite a similar degree of ovulatory dysfunction. This variability has important practical implications because the absence of a universally recognizable “classic” phenotype increases the risk of underdiagnosis in patients who do not correspond to the traditional stereotype of the disorder.

From a modern epidemiological perspective, PCOS should also be regarded as an amplifier of cardiometabolic risk. Affected women more frequently have impaired glucose tolerance, type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea and a possible increase in long term cardiovascular risk, independently of body mass index alone. This means that the prevalence of the syndrome should not be interpreted merely as the frequency of irregular menstrual cycles or infertility, but as the frequency of a multisystem condition that accompanies the patient throughout the reproductive course and, to some extent, beyond it.

PCOS does not have a single etiological cause that is both necessary and sufficient, but arises from the interaction of genetic predisposition, the metabolic environment, neuroendocrine regulation and ovarian function. The final result is a condition in which the ovarian follicle does not efficiently complete its maturation, ovulation becomes irregular or absent and androgen production is increased. The syndrome should therefore be understood as a self reinforcing pathological circuit rather than an isolated anatomical lesion.

One of the central components of the pathogenesis is insulin resistance, which is highly prevalent but not universal. When peripheral tissues become less responsive to insulin, the pancreas compensates by producing hyperinsulinemia. Excess insulin does not merely regulate blood glucose. It also acts as an endocrine cofactor, enhancing steroidogenesis in ovarian theca cells and promoting androgen synthesis. At the same time, it reduces hepatic production of SHBG, increasing the free and biologically active fraction of circulating androgens. This dual effect explains why many patients develop acne, hirsutism and ovulatory abnormalities against a background of metabolic dysfunction.

Within the ovary, androgen excess alters follicular growth. Early antral follicles are recruited but tend to arrest at intermediate stages of development, without effective selection of a dominant follicle. This leads to the accumulation of small peripheral follicles and absent or infrequent ovulation. From a pathophysiological perspective, this results in irregular or prolonged exposure of the endometrium to estrogen that is not adequately opposed by luteal progesterone because an ovulatory corpus luteum is absent. This mechanism accounts for irregular bleeding, prolonged amenorrhea and the increased risk of endometrial hyperplasia in chronic untreated forms.

The hypothalamic pituitary ovarian axis also contributes to the disorder. Many patients show a relatively imbalanced pattern of gonadotropin secretion, with increased pulsatile GnRH activity and functional predominance of luteinizing over follicle stimulating signaling. This environment further promotes androgen steroidogenesis in the theca and makes FSH dependent follicular maturation less efficient. The system is therefore not simply “switched off”, but functions in a disordered manner that sustains qualitatively abnormal hormone production.

Adipose tissue is not merely an energy reservoir, but an active endocrine organ. When visceral adiposity predominates, lipotoxicity, low grade inflammation, abnormal adipokine secretion and insulin resistance increase. These changes amplify the pathological interaction among the ovary, liver, skeletal muscle and pancreas. Obesity is therefore not required for diagnosis, but when present it acts as a biological multiplier, worsening both the reproductive and metabolic phenotypes.

The pathophysiology of PCOS directly explains its clinical manifestations. Hyperandrogenism causes acne, seborrhea, hirsutism and, in some cases, androgenetic alopecia. Anovulation causes oligomenorrhea, amenorrhea and anovulatory infertility. Hyperinsulinemia and metabolic dysfunction promote weight gain, impaired carbohydrate tolerance, metabolic steatotic liver disease and a greater risk of diabetes. The absence of regular luteal phases exposes the endometrium to disorganized estrogen stimulation and accounts for proliferative risk over time. In this sense, the syndrome is not a random collection of different symptoms, but the coherent expression of interconnected endocrine and metabolic mechanisms.

Finally, the pathogenesis of PCOS includes an often underestimated psychobiological dimension. Body image disturbance, anxiety, depression, insomnia and disordered eating behaviors are not merely emotional reactions to the diagnosis, but are intertwined with the clinical burden of the syndrome, the chronic nature of the symptoms and difficulty with weight management. The overall pathophysiology of PCOS must therefore be understood as an integration of reproductive function, metabolism, skin, endometrium and psychological well-being.

The clinical presentation of PCOS is heterogeneous and depends on the relative contribution of anovulation, hyperandrogenism and metabolic dysfunction. Some patients seek medical attention for a predominantly gynecological problem, such as infrequent or absent menstrual cycles; others present with skin manifestations; still others are evaluated for infertility or difficulty controlling body weight and blood glucose. This variability is one of the principal reasons for diagnostic delay.

During the medical history, menstrual history is often the starting point. Oligomenorrhea, secondary amenorrhea, irregular intervals between menstrual cycles and abnormal bleeding are common and reflect the absence of regular ovulation. In adolescents, these findings must be interpreted cautiously because some irregularity is physiological during the first years after menarche, but when the disturbance persists or is associated with other signs, suspicion of the syndrome becomes well founded. In adults, consistently infrequent or unpredictable menstrual cycles represent one of the most useful clinical indicators.

Hyperandrogenism manifests in different ways. Hirsutism is often the most specific clinical sign and generally affects the face, chin, chest, linea alba, lumbosacral region and inner thighs. In other patients, persistent acne, seborrhea or worsening acne beyond adolescence predominates, while a smaller proportion develops androgen pattern hair thinning. The severity of cutaneous signs does not always correlate perfectly with serum androgen levels because peripheral follicular sensitivity, ethnicity and cosmetic treatments may modify their expression.

Anovulatory infertility is a common mode of presentation. The patient reports prolonged unprotected intercourse without conception, often in the setting of irregular or absent menstrual cycles. In these cases, PCOS should not be considered only an ovarian cause of failed ovulation, but a syndrome that may also affect the endometrial environment, glucose metabolism and obstetric profile. Preconception assessment should therefore extend beyond ovulation induction alone.

On physical examination, in addition to signs of androgenization, it is important to assess central adiposity, increased waist circumference, acanthosis nigricans as a clinical marker of hyperinsulinemia, elevated blood pressure and signs of metabolic complications. Many patients report easy weight gain or particular difficulty losing weight despite dietary measures and physical activity, a finding that clinically suggests underlying energy and insulin dysfunction. However, not all patients are obese, and the absence of overweight must never discourage consideration of PCOS.

Psychological manifestations deserve explicit assessment during the medical history. Anxiety, depressed mood, frustration related to skin symptoms, infertility related stress, sleep disorders and impaired quality of life are common and may substantially influence treatment adherence. For some women, the main source of distress is not amenorrhea, but the social impact of hirsutism or the sense of losing control over their body. Recognizing this dimension is as important as interpreting laboratory tests.

More severe or prolonged forms may be associated with prediabetes, type 2 diabetes, dyslipidemia, obstructive sleep apnea, metabolic dysfunction associated steatotic liver disease and endometrial complications caused by persistent anovulation. The clinical picture therefore extends beyond the ovary and menstrual cycle. PCOS is a syndrome involving reproductive function, metabolism, skin and mental health with variable intensity but a unified pathophysiological basis.

Clinical suspicion of PCOS should arise when ovulatory irregularity is associated, even incompletely, with signs of androgenization. A young woman with oligomenorrhea and hirsutism represents the most typical presentation, but the syndrome should also be considered when menstrual cycles are irregular and hyperandrogenism is only biochemical, or when persistent acne and anovulatory infertility are accompanied by central overweight or signs of insulin resistance.

Suspicion should remain high in the presence of prolonged amenorrhea without pregnancy, particularly when the patient reports weight gain, worsening acne, androgen pattern hair loss or a family history of type 2 diabetes and ovulatory disorders. In gynecological practice, the diagnosis is often suggested by the menstrual history; in dermatological practice, by hirsutism or treatment resistant acne; in endocrinological practice, by glucose or metabolic abnormalities in a young woman. This initial fragmentation makes an integrated clinical perspective essential.

In patients seeking pregnancy, long, unpredictable or absent menstrual cycles should prompt early consideration of an ovulatory disorder. When apparent infertility is associated with signs of hyperandrogenism, suspicion of PCOS becomes particularly strong and supports a structured diagnostic pathway. Even in these cases, however, it is important to remember that not every case of infertility with multifollicular ovaries represents PCOS and that diagnosis cannot be based on a single ultrasound image.

Suspicion should be strengthened by indirect markers of metabolic dysfunction, including acanthosis nigricans, visceral obesity, a strong family history of diabetes or documented abnormal glucose levels at a young age. The syndrome often first manifests through menstrual or cutaneous abnormalities and only later through metabolic complications, although in some patients the cardiometabolic profile is already clinically relevant at diagnosis.

It is equally important to recognize when suspicion of PCOS should be reconsidered in favor of other diagnoses. Rapid virilization, deepening of the voice, clitoromegaly, marked muscle gain or very rapid progression of hyperandrogenism are not typical of the syndrome and should raise concern for other causes, including androgen secreting tumors or hypercortisolism. Similarly, amenorrhea with marked hypoestrogenism, galactorrhea, thyroid symptoms or signs of ovarian insufficiency requires a rigorous differential diagnosis.

During adolescence, diagnostic suspicion requires even greater caution. Many girls experience menstrual irregularity and acne during the first years after menarche without having a true syndrome. To prevent overdiagnosis, clinical reasoning must be based on persistence of the disorder, the presence of genuine hyperandrogenism and exclusion of other causes, rather than on multifollicular ovaries alone or isolated values that are difficult to interpret outside their clinical context.

The diagnosis of PCOS is clinical and biochemical and requires an orderly assessment that confirms the syndromic criteria and excludes alternative conditions. There is no single pathognomonic test. The objective is to demonstrate an appropriate combination of hyperandrogenism, ovulatory dysfunction and, when necessary, polycystic ovarian morphology or increased AMH in adults, while taking the patient’s age and reproductive stage into account. Assessment always begins with medical history, physical examination and characterization of menstrual history because the biology of the syndrome cannot be understood separately from the clinical phenotype.

In adults, updated international criteria retain the Rotterdam framework but provide more rigorous specifications. Diagnosis may be established when at least two of the following are present: clinical or biochemical hyperandrogenism, ovulatory dysfunction and polycystic ovaries on ultrasound or increased AMH, provided that other disorders mimicking the syndrome have been excluded. If an adult woman clearly has both ovulatory irregularity and hyperandrogenism, ultrasound and AMH are not required to confirm the diagnosis. In adolescents, however, both hyperandrogenism and ovulatory dysfunction are required, while ultrasound and AMH are not recommended for diagnosis because of their low specificity in this age group.

International diagnostic criteria for PCOS

• In adult women, diagnosis requires at least two of the following: clinical or biochemical hyperandrogenism, ovulatory dysfunction, polycystic ovaries on ultrasound or elevated AMH, after exclusion of other causes.
• In adolescents, diagnosis requires the coexistence of hyperandrogenism and ovulatory dysfunction; ovarian ultrasound and AMH should not be used routinely for diagnostic purposes.
• The principal alternative diagnoses must be excluded at minimum through measurement of TSH, prolactin and 17-hydroxyprogesterone, with expansion of the diagnostic evaluation when amenorrhea, virilization or clinical severity suggests different causes.
• Diagnosis should not be based on insulin measurement alone because currently available clinical insulin assays do not have sufficient utility in routine practice.

Assessment of biochemical hyperandrogenism requires technical care. Total and free testosterone or equivalent indices, androstenedione and DHEAS may contribute to the evaluation, but interpretation depends on the assay, the laboratory and the use of hormonal contraceptives. Clinically, significant hirsutism may already be highly suggestive even when androgen levels are only mildly elevated, whereas marked and rapidly progressive hyperandrogenemia requires exclusion of androgen secreting tumors and other endocrine disorders.

Ovarian ultrasound has an important but not independent role. In adults, it may document polycystic ovarian morphology and contribute to fulfillment of the diagnostic criteria when the first two elements are insufficient. However, the presence of multifollicular ovaries without hyperandrogenism or ovulatory dysfunction does not establish PCOS. In adolescents, ultrasound should not be used as a standard diagnostic criterion because pubertal physiology may mimic polycystic morphology, leading to overdiagnosis and inappropriate medicalization.

Once the syndromic diagnosis has been established, investigations should define metabolic, cardiovascular and endometrial risk. A lipid profile should be assessed from the time of diagnosis; blood pressure should be monitored periodically; glycemic status should be evaluated in all patients, preferably with a 75 g OGTT, which is the most accurate test for detecting impaired glucose tolerance in PCOS. If an OGTT cannot be performed, fasting glucose and HbA1c may be considered, although they are less accurate. In patients planning pregnancy or fertility treatment, glycemic status has strategic importance because of its association with obstetric risk.

The differential diagnosis should include thyroid dysfunction, hyperprolactinemia, nonclassic congenital adrenal hyperplasia, primary ovarian insufficiency, hypogonadotropic hypogonadism, Cushing syndrome and androgen secreting tumors. In women with severe amenorrhea, hypoestrogenism, substantial weight loss or extreme physical activity, the phenotype must be distinguished from functional hypothalamic hypogonadism. When the endometrium is persistently thickened or amenorrhea is prolonged, targeted assessment of hyperplasia risk may be required, including biopsy in appropriate cases.

In summary, the diagnosis of PCOS does not correspond to simply observing “polycystic” ovaries, but to the reasoned recognition of an endocrine and metabolic disorder defined by official criteria, exclusion of clinical mimics and simultaneous stratification of reproductive and cardiometabolic risk.

PCOS is a phenotypically variable syndrome, and its classification has clinical value because it helps link the predominant mechanisms with the objectives of care. The traditional distinction revolves around the presence or absence of the three cardinal elements: hyperandrogenism, anovulation and polycystic ovarian morphology. Some patients express the “complete” phenotype, while others present a partial combination, but all belong to the same pathological spectrum provided that international criteria are met and alternative diagnoses are excluded.

From a practical perspective, the first classification axis distinguishes predominantly reproductive phenotypes from predominantly metabolic phenotypes, while recognizing that the two domains often coexist. In forms dominated by ovulatory dysfunction, the patient is diagnosed because of irregular menstrual cycles, amenorrhea or infertility. In forms dominated by cutaneous hyperandrogenism, hirsutism, acne and alopecia predominate. In other cases, the metabolic profile, including insulin resistance, visceral adiposity, prediabetes or dyslipidemia, is more clinically relevant than the initial gynecological symptom.

A second level of classification concerns body weight. Some patients have PCOS associated with obesity, in which adipose tissue contributes strongly to the pathophysiology, while others have normal body weight and still have the complete syndrome despite less externally apparent metabolic risk. This distinction is useful but should not lead to oversimplification. A woman with normal body weight and PCOS does not necessarily have a “benign” form, just as a woman with obesity does not automatically have a more severe reproductive phenotype.

Clinical severity also depends on the duration of anovulation and the intensity of hyperandrogenism. Prolonged amenorrhea, persistent anovulation, marked hyperandrogenism, acanthosis nigricans, infertility, abnormal glucose metabolism and impaired quality of life indicate a syndrome with greater functional impact. In these situations, classification is not intended to assign an abstract label, but to determine therapeutic priorities, including endometrial protection, restoration of ovulation, metabolic management, improvement of skin symptoms or preparation for conception.

An increasingly relevant aspect of classification is the profile of long term risk. Some patients have a burden that is mainly cosmetic and menstrual, while others already exhibit dyslipidemia, impaired glucose tolerance, hypertension or suspected obstructive sleep apnea at a young age. In these patients, PCOS must be managed as a cardiometabolic as well as a reproductive syndrome, with more structured follow-up and a lower threshold for intervention through lifestyle measures and appropriate pharmacological treatment.

Finally, classification must consider the stage of life. During adolescence, the main challenge is avoiding both underdiagnosis and overdiagnosis; during the reproductive years, priorities often focus on the menstrual cycle, contraception, hyperandrogenism and fertility; during preconception and pregnancy, the focus shifts to ovulation, glycemic risk and obstetric outcomes; later, metabolic, cardiovascular and endometrial aspects become more prominent. The same syndrome therefore changes its clinical presentation over time while retaining a common pathophysiological core.

Treatment of PCOS must be personalized because no single therapy can simultaneously correct every domain of the syndrome. Objectives may include regulating menstrual cycles, protecting the endometrium, reducing acne and hirsutism, improving the metabolic profile, achieving ovulation and pregnancy or reducing the psychological burden of the disorder. Therapeutic selection must therefore begin with the patient’s priorities and an assessment of overall risk.

Lifestyle modification is the foundation of every strategy, particularly when overweight or obesity is present. Interventions involving diet, physical activity, sleep quality and sedentary behavior improve body weight, insulin sensitivity, body composition, quality of life and, in some cases, menstrual regularity and ovulation. There is no single diet that is universally superior for PCOS. The most important factors are sustainability, a strong therapeutic alliance and prevention of weight regain. Even without substantial weight loss, a healthier lifestyle produces clinically meaningful benefits.

In women who are not seeking pregnancy and have irregular menstrual cycles or hyperandrogenism, combined oral contraceptives are the first line pharmacological treatment. The rationale is twofold: they reduce ovarian androgen production and increase SHBG, thereby decreasing the free androgen fraction, while simultaneously regulating endometrial exposure and protecting against the risk of hyperplasia caused by chronic anovulation. Selection of the preparation should follow general contraceptive safety principles, with attention to thromboembolic risk and individual comorbidities.

Metformin has an important role particularly when the metabolic phenotype predominates, impaired glucose tolerance is present or insulin resistance is being targeted as a pathophysiological mechanism. It can improve metabolic parameters, promote greater menstrual regularity in some patients and help reduce the risk of progression to diabetes. It does not automatically replace combined oral contraceptives for the treatment of hirsutism, but is especially useful when metabolic health is the main clinical priority or when contraceptives are contraindicated or not tolerated.

Treatment of hirsutism and dermatological symptoms may require combined approaches. In addition to systemic hormonal therapy, cosmetic or physical measures, including laser hair removal and targeted dermatological treatment, are useful because clinical benefit must also include restoration of quality of life. When hirsutism is particularly distressing, ignoring this dimension results in inadequate treatment of the syndrome even when menstrual cycles improve. Dermatological management should therefore be integrated with endocrinological and gynecological care.

In women with anovulatory infertility, treatment has a different objective. According to updated international recommendations, letrozole is the first line pharmacological treatment for ovulation induction in the absence of other significant infertility factors. Clomiphene citrate and metformin retain a role in selected settings or when letrozole is unavailable or inappropriate, but they no longer occupy the same position in the treatment hierarchy for every patient. Selection nevertheless requires assessment of tubal patency, semen analysis, age and duration of infertility.

Protection of the endometrium is an objective that must not be overlooked. In patients with amenorrhea or marked oligomenorrhea, induced cycles or adequate progestin exposure must be ensured when combined oral contraceptives are not used. This step is crucial because it reduces the risk of endometrial hyperplasia caused by unopposed estrogen exposure. In some patients, particularly those with obesity, diabetes or long standing amenorrhea, vigilance regarding this issue must be especially rigorous.

Finally, effective treatment of PCOS must include screening and management of anxiety, depression, eating disorders, obstructive sleep apnea, dyslipidemia and glucose abnormalities. The syndrome is not adequately treated by merely “restoring the menstrual cycle”. Appropriate care requires multidimensional management, patient education, realistic goal setting and adaptation of the strategy over time according to reproductive stage and treatment response.

Follow-up of PCOS must be structured and continuous because the syndrome evolves with age, body weight, lifestyle changes and transitions among different objectives, including contraception, pursuit of pregnancy and metabolic prevention. Monitoring is not intended solely to verify treatment efficacy, but also to detect complications early, including in young patients who appear to have few symptoms.

Surveillance should begin with the symptoms that led to diagnosis. Menstrual frequency and regularity, abnormal bleeding, the course of acne and hirsutism, changes in body weight, treatment tolerability and quality of life should be reassessed periodically. In patients treated with combined oral contraceptives, adherence, safety profile and clinical response should be monitored; in those receiving metformin, gastrointestinal effects, metabolic efficacy and consistency with the agreed goals should be reviewed.

Metabolic monitoring is central. The lipid profile, blood pressure and glycemic status should be reassessed at intervals appropriate to individual risk. Glucose metabolism should be reevaluated over time, preferably at shorter intervals in the presence of obesity, a family history of diabetes, previous OGTT abnormalities or planned pregnancy. PCOS increases the risk of abnormal glucose metabolism independently of BMI, and screening must therefore not be restricted to patients with obesity.

Attention to the endometrium is part of appropriate follow-up. In women with very infrequent menstrual cycles or persistent amenorrhea, an effective strategy of progestin protection or bleeding regulation must be ensured. Persistent prolonged amenorrhea, endometrial thickening or abnormal bleeding requires timely reassessment because proliferative risk increases when anovulation remains untreated for extended periods.

Follow-up should also include the psychological dimension. Anxiety, depression, sleep disorders, body dissatisfaction and disordered eating may emerge or worsen over time, influencing adherence and clinical outcomes. Effective monitoring includes explicit questions about mental well-being and the impact of symptoms on daily life, without relegating these issues to a secondary role. In PCOS, therapeutic success does not correspond only to improvement in biochemical parameters.

When pregnancy becomes the objective, follow-up changes perspective. Ovulation, partner factors, age related fertility potential, preconception glycemic status and the treatment plan must be reassessed. The OGTT becomes particularly relevant before conception or during early pregnancy because PCOS is associated with a greater risk of gestational hyperglycemia and obstetric complications. Similarly, adolescents considered “at risk” but not yet suitable for a definitive diagnosis should be monitored periodically to avoid both premature labeling and failure to recognize a true disorder.

Ultimately, follow-up of PCOS should be understood as a pathway of chronic disease management. The syndrome requires more than occasional assessments related to menstrual cycles or infertility. It requires surveillance capable of accompanying the patient through the different stages of reproductive and metabolic life, with periodic adjustment of priorities, treatments and preventive measures.

The prognosis of PCOS is generally favorable when the syndrome is recognized early and managed through a personalized approach, but it cannot be considered “trivial” because its clinical burden depends on the persistence of anovulation, the intensity of hyperandrogenism and, above all, the patient’s metabolic profile. In many women, symptoms can be controlled effectively and fertility can be restored through appropriate strategies, but the syndrome tends to remain clinically relevant over the long term even when menstrual dysfunction becomes less apparent.

Reproductive complications include anovulatory infertility, subfertility, an increased risk of metabolic complications during pregnancy and preconception difficulties related to obesity, insulin resistance and abnormal glycemic status. Reproductive prognosis is nevertheless often favorable with appropriate treatment, particularly when body weight, ovulation and concomitant infertility factors are addressed systematically. PCOS therefore does not imply irreversible sterility, but represents a condition requiring appropriate assessment and timing.

One of the most important complications is endometrial. Chronic anovulation causes prolonged estrogen exposure without regular progestin opposition and may promote endometrial hyperplasia and, over the long term, increase the risk of endometrial cancer. The absolute risk remains relatively low in young women, but increases with prolonged amenorrhea, obesity, diabetes and persistent endometrial thickening. This is the pathophysiological reason why menstrual regulation or progestin protection are not cosmetic measures, but substantial preventive interventions.

From a metabolic perspective, the syndrome is associated with a higher frequency of impaired glucose tolerance, type 2 diabetes, dyslipidemia, hypertension, metabolic dysfunction associated steatotic liver disease and obstructive sleep apnea. PCOS should therefore be considered a condition of systemic vulnerability rather than a simple variation in the menstrual cycle. Metabolic prognosis is strongly influenced by body weight, fat distribution, family history of diabetes, physical activity and the timeliness of lifestyle intervention.

Psychological complications carry genuine clinical importance. Depression, anxiety, body image disturbance, social distress caused by hirsutism and acne, reproductive stress and eating disorders may impair quality of life and treatment adherence to an extent equal to or greater than the hormonal abnormalities themselves. A favorable prognosis therefore requires these elements to be recognized and treated rather than merely recorded as marginal comorbidities.

Prognosis also depends on the quality of treatment. Early lifestyle intervention, regular glycemic monitoring, endometrial protection, appropriate treatment of hyperandrogenism and a properly planned reproductive pathway substantially reduce the burden of disease. Conversely, delayed diagnosis, minimization of symptoms and fragmented care promote chronic distress and the development of preventable complications. PCOS is therefore a syndrome whose effects can often be controlled, but it requires serious follow-up and a long term clinical perspective.

Overall, polycystic ovary syndrome has a generally favorable prognosis in terms of survival and the possibility of symptom control, but remains a condition with a major impact on fertility, metabolism, the endometrium and mental health. The true prognostic difference depends not only on the initial severity of the phenotype, but on the capacity to recognize the syndrome as a chronic multidimensional disorder rather than a simple menstrual irregularity.